News
ITRM
1.500
-5.67%
-0.090
ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q4 2023
Iterum Therapeutics reported earnings per share of -81 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. It was above the analyst estimate of -93 cents per share. The company just reported results for fourth quarter.
Investorplace · 4h ago
Update: Iterum Therapeutics Q4 Adjusted EPS $(0.81) Beats $(0.94) Estimate
Benzinga · 7h ago
Iterum Therapeutics Non-GAAP EPS of -$0.81
Iterum Therapeutics sold 2.9 million ordinary shares under an at-the-market offering for $7.1 million. The company posted a Q4 non-GAAP EPS of -$0.81. The firm has a cash runway into 2025.
Seeking Alpha · 9h ago
Iterum Therapeutics Q4 2023 GAAP EPS $(0.94), Inline, Cash Position $23.9M
Benzinga · 9h ago
Earnings Scheduled For March 28, 2024
Universal Stainless is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. Walgreens Boots Alliance is likely to report earnings for its fourth quarter. Companies Reporting Before The Bell include Shimmick and Universal Stainless. Companies reporting after the bell include INmune Bio and Oxford Industries.
Benzinga · 10h ago
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Barchart · 14h ago
Iterum Therapeutics's Earnings: A Preview
Iterum Therapeutics is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Analysts estimate the company will report an earnings per share of $-0.93. Last quarter the company missed EPS by $0.29. Shares of the company are up 57.25% in the last 52 weeks.
Benzinga · 1d ago
Notable earnings before Thursday's open
Seeking Alpha · 1d ago
Weekly Report: what happened at ITRM last week (0318-0322)?
Weekly Report · 3d ago
Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more
Several key companies are set to release their earnings reports for the week of March 25 to 29. Walgreens Boots Alliance, Carnival, GameStop and more are among the companies scheduled to report next week. The week is shortened by a market holiday on Friday and will be shortened to one day.
Seeking Alpha · 4d ago
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
Iterum Therapeutics plc will release its fourth quarter and full year 2023 financial results before the open of the U.S. Financial markets on March 28, 2024. The company is focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens. Management will host a conference call.
Barchart · 03/21 15:30
12 Health Care Stocks Moving In Wednesday's After-Market Session
XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 13.9% to $2.71 during Wednesday's after-market session. The company's Q4 earnings report came out 2 days ago. Jaguar Health and Leap Therapeutics were among the gainers.
Benzinga · 03/20 21:34
Weekly Report: what happened at ITRM last week (0311-0315)?
Weekly Report · 03/18 12:05
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
Iterum Therapeutics plc will participate in a virtual H.C. Wainwright @Home Fireside Chat on March 21, 2024. The company is focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens. The virtual chat will discuss the company's lead program, oral sulopenem.
Barchart · 03/15 07:00
Weekly Report: what happened at ITRM last week (0304-0308)?
Weekly Report · 03/11 12:00
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
NASDAQ · 03/07 12:57
BUZZ-U.S. STOCKS ON THE MOVE-Silver miners, Albemarle, Pfizer
Federal Reserve Chair Jerome Powell says central bank expects to reduce benchmark interest rate later this year. The Dow Jones Industrial Average was up 0.28% at 38,694.64. Top three S&P 500 percentage gainers: Albemarle, DexCom, Pfizer.
Reuters · 03/06 19:09
Iterum spikes on accelerated timeline for FDA filing
Seeking Alpha · 03/06 18:40
Iterum Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 03/06 17:15
HC Wainwright & Co. Reiterates Buy on Iterum Therapeutics, Maintains $6 Price Target
Benzinga · 03/06 17:05
More
Webull provides a variety of real-time ITRM stock news. You can receive the latest news about Iterum Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About ITRM
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.